Resumen

JAYAWEERA, Dushyantha T, SCERPELLA, Ernesto G, RODRIGUEZ, Allan E et al. Trombocitopenia asociada a infección con virus de inmunodeficiencia humana tipo 1 (HIV-1): Tratamiento con danazol. Rev Med Hered, oct. 1996, vol.7, no.4, p.150-153. ISSN 1018-130X.

Objective: To evaluate the efficacy of danazol for the treatment of thrombocytopenia associated with human immunodeficiency virus tipe 1 (HIV-1) infection. Patients and Methods: Retrospective, case series study. Eight patients with thrombocytopenia associated with HIV-1 infection, and treated with danazol 300 mg to 800 mg a day for more than 3 months were identified. Follow-up ranged from 3 months to 2 years. Response to treatment was defined as a 25% increase in platelet count from pre-treatment values. Results: The mean platelet count before danazol therapy. Mean platelet counts and standard deviations at 12 and 24 months of therapy were 104± 108 x 10⁹/L (range, 19-88 x 10⁹/L). Seven (87%) of 8 patients responsed to danazol therapy. Mean platelet counts and standard deviations al 12 and 24 months of therapy were 104± 108 x 10⁹/L, and 112± 28 x 10⁹/L. There was a trend towards an increase in platelet counts during treatment. Conclusion: Danazol may be effective in HIV-1 induced trombocytopenia. (Rev Med Hered 1996; 7: 150-153).

Palabras llave: Thrombocytopenia; Danazol; AIDS; HIV.